CLAIMS

1. Use of an mPGES-1 inhibitor in the manufacture of a medicine for prevention and/or treatment of chronic prostatitis/chronic pelvic pain syndrome, wherein the mPGES-1 inhibitor is a compound selected from the group consisting of N-(3-chloro-2-methylphenyl)-2-(methoxymethyl)-6-({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazole-4-carboxamide and N-(3-chloro-2-methylphenyl)-2-[1-(trifluoromethyl)cyclopropyl]-6-({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazole-4-carboxamide, or a tautomer of the compound, or a pharmaceutically acceptable salt thereof.

2. Use of N-(3-chloro-2-methylphenyl)-2-(methoxymethyl)-6-({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazole-4-carboxamide 4-methylbenzenesulfonate in the manufacture of a medicine for prevention and/or treatment of chronic prostatitis/chronic pelvic pain syndrome.

3. Use of N-(3-chloro-2-methylphenyl)-2-[1-(trifluoromethyl)cyclopropyl]-6-({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazole-4-carboxamide in the manufacture of a medicine for prevention and/or treatment of chronic prostatitis/chronic pelvic pain syndrome.